@FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev
@MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce
@DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce
> Turkey is gearing up to produce its own medical equipment rather than importing the products. Story
> Regulators want to know why Biosense Technologies' iPhone app that lets diabetics check levels of blood, protein and other substances in their urine isn't FDA-cleared for use. Story
> Medical device manufacturer Advant Medical has committed a sizeable investment toward expanding its Galway, Ireland, plant. Story
> Johnson & Johnson ($JNJ) is suing Shasta Technologies, saying the company's logo infringes on its LifeScan unit's trademark. Article
> In a study, Biomet found that patients who received its Oxford Partial Knee implant were 1.8 times more likely than total-knee-replacement recipients to report that their knee felt normal and 2.7 times more likely to be happy with their ability to perform routine tasks. News
> Nephosity won the FDA's OK to start marking an imaging viewing mobile app for diagnostic use. Story
> Synthes founder Hansjӧrg Wyss has given another $125 million to Harvard to advance the work of The Wyss Institute for Biologically Inspired Engineering, itself launched a few years back from Wyss's initial $125 million gift. Story
Biotech News
@FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech
@JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce
@RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce
> Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma. Article
> Pfizer denies knowledge of acquired companies' failures in East German drug trials. Story
> Merck Serono CEO stakes out Boston biotech startups. More
Pharma News
@FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma
@EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce
> BRIC markets turning out to be tougher to mine than expected. More
> Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board. Story
> Novartis apologizes over Diovan study as probe shows employee involvement in trials. Article